AD-RESYL, Silab’s new patented natural active ingredient dedicated to the comfort and resilience of atopic skin. The molecule was specifically developed to prevent the clinical signs of atopic dermatitis by prolonging remission periods following treatment with corticosteroid therapy.
“With the launch of AD-RESYL, Silab offers a dermo-cosmetic approach of atopic dermatitis,” says Brigitte Closs-Gonthier, Deputy Managing Director for Research. “Our goal was to decrease the frequency of inflammatory periods, with a molecule meeting our criteria: efficacy, naturality, and safety.”
Silab screened no less than 57 raw materials to launch this new active. The French laboratory eventually chose an extract of Ophiopogon japonicas (dwarf lilyturf), a plant with tuberous roots known for their resistance to drought and native to China and South Korea.
The efficacy of AD-RESYL was demonstrated by a series of in vitro and in vivo assessments. Silab used a 3D model reproducing a skin affected by atopic dermatitis. Tests were also on cohorts of Caucasian and Asian children and/or adults.
“AD-RESYL meets the many expectations of patients on the lookout for care and comfort to restore health to their skin: it benefits from clinically demonstrated efficacy, optimum skin tolerance, and a controlled natural raw material,” said Silab.
To double size 5 years
The launch of AD-RESYL is the result of over 5 years of research by multidisciplinary teams made up of molecular biologists, bioinformaticians, clinical experts and process engineers.
In the wake of this innovation, Silab intends to invest in the long term to address the markets of dermo-cosmetics and dermatology. “Our conviction is that the skin care market is moving towards an increased medicalization,” explains Xavier Gaillard, Silab’s Deputy General Manager. “It is less about beauty and more about well-being.”
In order to extend its knowledge of healthy skin to the problems of compromised skin, Silab has created the Silab softcare division, which is dedicated to the research, production and marketing of innovative natural active ingredients specifically designed to care for dermatological disorders by restoring the homeostasis of healthy skin. “Silab softcare relies on Silab’s expertise, capacity for innovation and responsive organization to broaden acquired knowledge of healthy skin to the problems of compromised skin,” adds the company.
According to company executives, Silab softcare should strongly contribute to help the group to reach its target to double size within 5 years. In 2015, Silab’s achieved a turnover of EUR 40 million, 60% on export markets.